Annovis Bio ANVS 深 沪
等待开盘 09-13 09:30:00 美东时间
2.45
+0.060
+2.51%
华盛通- 最 高2.48
- 今 开2.39
- 成交量 23.36万股
- 最 低 2.3631
- 昨 收 2.39
- 总市值 4774.12万
- 52周最高 10.54
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 1.11
- 委 比 -59.81%
- 总股本 1948.62万
- 历史最高 132.00
- 量 比 1.33
- 振 幅 4.89%
- 历史最低 1.11
- 每 手 1
- 风险率 2.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-03 20:25
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical company developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's, announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 12:00-12:30 pm EDT in New York City.
09-02 12:00
Annovis Bio Q2 EPS $(0.32) Beats $(0.40) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.40) by 20.6 percent. This is a 27.27 percent increase over losses of $(0.44) per share from the same
08-13 04:37
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
Annovis Bio provided updates on its Phase 3 Alzheimer's disease trial, with 76 U.S. sites secured and over 400 patients screened. The company also strengthened its intellectual property by transferring patent families to crystal buntanetap. Financially, cash increased to $17.1 million, while R&D expenses decreased slightly. Net loss per share improved to $0.32, reflecting progress in enrollment and cost management.
08-12 20:05
Annovis Completes Full Patent Transfer to Crystal Buntanetap
<p>Annovis Bio, Inc. announced the successful transfer of all patents for buntanetap, covering both its original semi-crystalline and newly developed crystalline forms. These 13 patent families ensure global coverage until 2046. The new crystalline form offers improved stability and comparable pharmacokinetics, with bioequivalence demonstrated in studies presented at AAIC 2025. The FDA approved the crystalline form for a pivotal Phase 3 trial in ...
08-07 12:00
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) rose sharply in pre-market tradi...
07-22 17:39
Annovis to Attend the AAIC 2025 with Four Poster Presentations
Annovis Bio, a clinical-stage company focusing on neurodegenerative diseases like Alzheimer's and Parkinson's, announced its senior management will participate in the Alzheimer's Association International Conference (AAIC) 2025 in Toronto. The company will present four scientific posters detailing advancements in its Alzheimer’s clinical program and pharmacokinetic studies of its lead drug candidate, buntanetap. Topics include Phase III study des...
06-26 12:00
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 duri...
06-26 01:06
Annovis Bio Approves Board Elections and Auditor Appointment
An update from Annovis Bio ( ($ANVS) ) is now available. On June 17, 2025, Anno...
06-24 05:48
Annovis Bio Announces It Received NYSE Acceptance Letter Granting The Co 18-Month Period To Maintain Listing
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
06-19 18:38
